$4.5 Million Could Unlock a Major Cannabis Market

Sponsored:

Friday, August 21, 2026

New York's legal cannabis market has spent years working through licensing delays, illicit competition and a difficult rollout, but the opportunity is becoming harder for established operators to ignore. With more than 700 dispensaries and demand shifting toward regulated channels, existing cultivation capacity and retail infrastructure offer a faster route into the state than building from scratch.

Shares of Grown Rogue International Inc. (CSE: GRIN) (OTCQB: GRUSF) are climbing Friday after the company announced the first steps toward acquiring PharmaCann's New York license and assets, including a substantial cultivation and manufacturing facility and four existing Verilife dispensaries.

At the center of the deal is PharmaCann's Hamptonburgh facility, with approximately 24,000 square feet of indoor flower canopy, 16,000 square feet of light-deprivation greenhouse canopy, and manufacturing and post-harvest infrastructure. Before production slowed substantially in early 2026, the facility averaged more than 2,000 pounds of flower per month.

The four dispensaries have averaged aggregate monthly sales of approximately $1.7 million to $2.0 million over the past 18 months. Metropolitan Albany and Syracuse serve both medical and adult-use customers, while metropolitan Buffalo and the Bronx are medical-only.

Grown Rogue is pursuing the acquisition through Grown Rogue New York, a 51/49 joint venture with a capital partner that has contributed $10 million for a 49% preferred equity interest and committed another $5 million through a drawable term loan. Grown Rogue estimates total project costs, including the acquisition, capital expenditures and working capital, at approximately $12 million.

The preferred is convertible at the partner's option into Grown Rogue subordinate voting shares at escalating prices beginning at $0.55, which the company estimates at roughly 18.2 million shares, or about 7% dilution, if converted today.

The anticipated purchase price is approximately $4.5 million, including an inventory adjustment, with $3 million payable following regulatory approval. Definitive agreements are expected within four weeks, and the acquisition remains subject to those agreements, regulatory approval and customary closing conditions. Grown Rogue New York is managing day-to-day operations and funding the transition in the meantime.

Grown Rogue expects cost reductions implemented over its first six months of oversight to lower annual costs by approximately $20 million, and anticipates the New York operations could become after-tax operating cash flow positive within nine months. Within 18 months, management is targeting approximately $600,000 in monthly after-tax operating cash flow. Those forecasts rest on lease adjustments that account for more than 75% of the anticipated savings and an assumption that Section 280E will no longer apply to the operations by 2027.

The Hamptonburgh cultivation operation is expected to require six to nine months to ramp production.

Shares of GRIN are up 11.7% to C$0.67, while GRUSF is ahead 10.6% to $0.4838 in Friday morning trading.

Sponsored: